A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer

NCT07401381 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Hormone Receptor Positive Early Breast Cancer

Interventions

DRUG: US-sourced oral Femara® + Letrozole SIE
DRUG: EU sourced oral Femara® + Letrozole SIE

Sponsor

Rovi Pharmaceuticals Laboratories